In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...
FARXIGA is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor proven to significantly reduce the risk of mortality in patients with CKD. 8-14 The DAPA-CKD Phase III trial showed that, on top ...
FARXIGA is the first medicine to significantly prolong survival in a renal outcomes trial in patients with chronic kidney disease with and without type 2 diabetes WILMINGTON, Del.--(BUSINESS WIRE)-- ...
HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results